Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Sarepta Therapeutics

Selecta Biosciences Inc. (NASDAQ: SELB) and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have announced that they had entered into a research license and option agreement.

How Sarepta and Selecta Bio Are Taking the Fight to DMD

Application of ImmTOR plus Sarepta’s investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies Application of ImmTOR plus Sarepta’s investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies

Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases

It's Time To Invest In Selecta Biosciences As They Ink Massive $100 Million Upfront Deal

Selecta Biosciences Is A Buy After Major Deal

Is  (SELB) Outperforming Other Medical Stocks This Year?

Is Selecta Biosciences (SELB) Stock Outpacing Its Medical Peers This Year?

WATERTOWN, Mass., June  15, 2020  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Raymond James 2020 Human Healthcare Innovation Conference on Thursday, June 18 at 10:20 a.m. Eastern Time.

Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference

A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.

Here's Why Selecta Biosciences Is Tumbling Today

STOCKHOLM, and WATERTOWN, Mass., June 11, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced that the companies have entered into a strategic licensing agreement for the product candidate SEL-212. SEL-212...

Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout

- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need for the treatment of chronic refractory gout -

Sobi and Selecta - announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Selecta (SELB) Stock a Solid Choice Right Now?

WATERTOWN, Mass., May  26, 2020  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 8:30 a.m. Eastern Time.

Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2020 Results - Earnings Call Transcript

Everi

Geron

Menlo Therapeutics

ORBCOMM

Plug Power

Rockwell Medical

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

7 Penny Stocks To Buy with Massive Upside Potential

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2019 Results - Earnings Call Transcript

SEL-212 can emerge as game changer in chronic refractory gout indication.

Selecta Biosciences: An Innovative Immunomodulatory Player For 2020

– Selecta eligible to receive upfront and milestone payments of over $240 million –

AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

– Top-line statistical results expected mid-2020 –

Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

WATERTOWN, Mass., Dec.  19, 2019  (GLOBE NEWSWIRE) --  Selecta Biosciences, Inc.  (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it has entered into definitive agreements to sell securities in a private placement with a group of institutional investors and certain members of the Company’s Board of Directors. The lead institutional investors in the private placement were Vivo Capital LLC, Mangrove Partners, EcoR1 Capital LLC, BVF Partners L.P., and Boxer Capital LLC. The transaction is expected to result in gross proceeds to the company of approximately $70 million, before deducting placement agent fees and other offering expenses.

Selecta Biosciences Announces $70 Million Private Placement

– Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s  ImmTOR™  platform –

Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors

WATERTOWN, Mass., Nov.  12, 2019  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19 at 1:50 p.m. Eastern Time. A live webcast and a copy of the presentation will be available on the Investors & Media section of the Selecta website at www.selectabio.com.

Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2019 Results - Earnings Call Transcript

WATERTOWN, Mass., Oct.  24, 2019  (GLOBE NEWSWIRE) --  Selecta Biosciences, Inc.  (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that data from the company’s completed Phase 2 dose ranging study of SEL-21 (NCT02959918) for the treatment of chronic refractory gout will be presented at the upcoming 2019 American College of Rheumatology (ACR) Annual Meeting being held from November 8-13, 2019 in Atlanta, GA.

Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting

WATERTOWN, Mass., Oct.  23, 2019  (GLOBE NEWSWIRE) --  Selecta Biosciences, Inc.  (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today presented new preclinical data from its gene therapy program at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress from October 22-25, 2019 in Barcelona, Spain.

Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2019 Results - Earnings Call Transcript

Selecta Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

News for Selecta Biosciences Stock (SELB)